drugset
Drugs / zelicapavir
last change Jul 2026 re-read 2 minutes ago

zelicapavir

also known as EDP-938

Small molecule

Developed for
respiratory syncytial virus infectious disease
Investigated by
Enanta Pharmaceuticals, Inc · Pharmaceutical Research Associates · AMS-PHPT Research Collaboration, Chiang Mai University · PENTA Foundation · PPD Development, LP · hVIVO Services Limited

Trials 13 · a red edge is where a trial was stopped

today NCT07482657 · Ph 2 NCT06601192 · Ph 1 NCT05568706 · Ph 2 NCT04816721 · Ph 2 NCT04633187 · Ph 2 NCT04927793 · Ph 1 NCT04871724 · Ph 1 NCT04498741 · Ph 1 NCT04196101 · Ph 2 NCT03755778 · Ph 1 NCT03750383 · Ph 1 NCT03691623 · Ph 2 NCT03384823 · Ph 1
2018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 17 trials
Phase 1 NCT06601192 Jul 2024 → Feb 2025 respiratory syncytial virus infectious disease Enanta Pharmaceuticals, Inc Completed No outcome recorded
Phase 1 NCT04927793 May → Jul 2021 respiratory syncytial virus infectious disease Enanta Pharmaceuticals, Inc Completed No outcome recorded
Phase 1 NCT04871724 Mar 2021 respiratory syncytial virus infectious disease Enanta Pharmaceuticals, Inc Completed No outcome recorded
Phase 1 NCT04498741 Jul 2020 → May 2021 respiratory syncytial virus infectious disease Enanta Pharmaceuticals, Inc Completed No outcome recorded
Phase 1 NCT03755778 Nov 2018 → Jan 2019 respiratory syncytial virus infectious disease Enanta Pharmaceuticals, Inc Completed No outcome recorded
Phase 1 NCT03750383 Nov 2018 respiratory syncytial virus infectious disease Enanta Pharmaceuticals, Inc Completed No outcome recorded
Phase 1 NCT03384823 Dec 2017 → Jul 2018 respiratory syncytial virus infectious disease Enanta Pharmaceuticals, Inc Completed No outcome recorded
Phase 26 trials
Phase 2 NCT07482657 Jul → Dec 2026 expected respiratory syncytial virus infectious disease Enanta Pharmaceuticals, Inc Recruiting No outcome recorded
Phase 2 NCT05568706 Nov 2022 → Jun 2025 respiratory syncytial virus infectious disease Enanta Pharmaceuticals, Inc Completed No outcome recorded
Phase 2 NCT04816721 Apr 2022 → Aug 2024 respiratory syncytial virus infectious disease Enanta Pharmaceuticals, Inc Completed No outcome recorded
Phase 2 NCT04633187 Jul 2021 → May 2023 respiratory syncytial virus infectious disease Enanta Pharmaceuticals, Inc Terminated No outcome recorded
Phase 2 NCT04196101 Jan 2020 → Jan 2022 respiratory syncytial virus infectious disease Enanta Pharmaceuticals, Inc Completed No outcome recorded
Phase 2 NCT03691623 Oct 2018 → Sep 2019 respiratory syncytial virus infectious disease Enanta Pharmaceuticals, Inc Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 15 sources stand behind the page.

FieldValueCited text
Known as zelicapavir ClinicalTrials.gov intervention name — accepted as the source's own label NCT06601192 ↗
1

NCT07482657 ↗
Known as EDP-938 ClinicalTrials.gov intervention name — accepted as the source's own label NCT03691623 ↗
10

NCT04498741 ↗

NCT04816721 ↗

NCT03755778 ↗

NCT05568706 ↗

NCT03750383 ↗

NCT03384823 ↗

NCT04871724 ↗

NCT04196101 ↗

NCT04633187 ↗

NCT04927793 ↗
Action Inhibit “EDP-938, a nonfusion replication inhibitor of RSV, acts by modulating the viral nucleoprotein.” PMID 35172056 ↗ Feb 2022
Modality Small molecule — CHEMBL4475481 ↗
Route Oral “EDP-938 Dose 1, Dose 2, Dose 3, Dose 4, Dose 5, and Dose 6 oral suspension, once daily in one single administration” NCT03384823 ↗